What changed: Cervical cancer
Every dated change on the records linked to Cervical cancer, newest first: approvals and regulatory steps on its medicines, trials that reported, guideline versions, milestones, and when this page itself was checked. Dates come from the records; none is inferred. Orientation, not medical advice.
September 2026 · 1
2026 · 1
2025 · 2
- 2025ApprovalTisotumab vedotinTisotumab vedotin approved in EU
Recurrent/metastatic cervical after systemic therapy; 28 Mar 2025
- 2025MilestoneHPV DNA testing and self-samplingAt-home HPV self-test approved in the US; single-dose schedules adopted by 60+ countries
A milestone in how this cancer is treated.
September 2024 · 1
April 2024 · 1
2024 · 4
- 2024ApprovalCadonilimabCadonilimab approved in China
First-line persistent/recurrent/metastatic cervical cancer with chemotherapy ± bevacizumab; first-line gastric cancer with chemotherapy
- 2024ApprovalIparomlimab and tuvonralimabIparomlimab and tuvonralimab approved in CN
Recurrent or metastatic cervical cancer after platinum chemotherapy
- 2024Trial resultCOMPASSION-16 / AK104-303COMPASSION-16 / AK104-303 reported
OS HR 0.
- 2024MilestoneKEYNOTE-A18 / ENGOT-cx11 / GOG-3047Pembrolizumab approved with chemoradiation (Jan); tisotumab full approval (Apr); FDA approves HPV self-collection (May); COMPASSION-16 published; SHAPE trial supports simple hysterectomy; Scotland reports zero cancers in fully vaccinated cohort
A milestone in how this cancer is treated.
2023 · 6
- 2023Trial resultBEATcc / ENGOT-Cx10 / GOG-3030BEATcc / ENGOT-Cx10 / GOG-3030 reported
OS 32.
- 2023Trial resultDESTINY-PanTumor02DESTINY-PanTumor02 reported
Endometrial ORR 57.
- 2023Trial resultinnovaTV 301 / ENGOT-cx12 / GOG-3057innovaTV 301 / ENGOT-cx12 / GOG-3057 reported
OS 11.
- 2023Trial resultINTERLACEINTERLACE reported
5-year OS 80% vs 72% (HR 0.
- 2023Trial resultKEYNOTE-A18 / ENGOT-cx11 / GOG-3047KEYNOTE-A18 / ENGOT-cx11 / GOG-3047 reported
PFS HR 0.
- 2023MilestoneKEYNOTE-A18 / ENGOT-cx11 / GOG-3047KEYNOTE-A18 and INTERLACE positive; BEATcc and innovaTV 301 positive
Four practice-changing phase 3 results presented at ESMO 2023.
2022 · 3
- 2022ApprovalCadonilimabCadonilimab approved in China
Recurrent/metastatic cervical cancer after platinum
- 2022Trial resultKEN SHE (single-dose HPV vaccine)KEN SHE (single-dose HPV vaccine) reported
Single-dose efficacy 97.
- 2022MilestoneKEN SHE (single-dose HPV vaccine)WHO endorses single-dose HPV vaccination (KEN SHE); OUTBACK negative
A milestone in how this cancer is treated.
September 2021 · 1
2021 · 7
- 2021ApprovalTisotumab vedotinTisotumab vedotin approved in US
Recurrent/metastatic cervical cancer after chemotherapy (full 2024)
- 2021Trial resultEMPOWER-Cervical 1 / GOG-3016 / ENGOT-cx9EMPOWER-Cervical 1 / GOG-3016 / ENGOT-cx9 reported
OS 12.
- 2021Trial resultIARC India HPV vaccine dose study (one, two or three doses)IARC India HPV vaccine dose study (one, two or three doses) reported
Efficacy against persistent HPV 16/18 infection: 95.
- 2021Trial resultKEYNOTE-826KEYNOTE-826 reported
OS 26.
- 2021Trial resultOUTBACK / ANZGOG 0902 / GOG-0274OUTBACK / ANZGOG 0902 / GOG-0274 reported
5-year OS 72% vs 71%; no benefit.
- 2021MilestoneKEYNOTE-826KEYNOTE-826: first-line chemo-immunotherapy; tisotumab vedotin accelerated approval; EMPOWER-Cervical 1
A milestone in how this cancer is treated.
- 2021MilestoneTisotumab vedotinTisotumab vedotin approved
A milestone in how this cancer is treated.
2020 · 1
2018 · 2
August 2014 · 1
2014 · 3
- 2014ApprovalBevacizumabBevacizumab approved in US
Platinum-resistant ovarian cancer with chemotherapy; recurrent/metastatic cervical cancer with chemotherapy
- 2014Trial resultMumbai VIA cervical screening trial (Tata Memorial)Mumbai VIA cervical screening trial (Tata Memorial) reported
Cervical cancer mortality rate ratio 0.
- 2014MilestoneBevacizumabBevacizumab extends survival in advanced disease (GOG-0240); Gardasil 9 approved; HPV primary screening approved in the US
A milestone in how this cancer is treated.
2009 · 2
- 2009ApprovalHPV bivalent vaccine (types 16 and 18)HPV bivalent vaccine (types 16 and 18) approved in US
Prevention of cervical cancer and precursor lesions caused by HPV 16 and 18 in females 10 to 25 (discontinued in the US 2016)
- 2009Trial resultOsmanabad cervical screening trial (HPV testing vs cytology vs VIA)Osmanabad cervical screening trial (HPV testing vs cytology vs VIA) reported
Cervical cancer deaths HR 0.
2007 · 1
2006 · 5
- 2006ApprovalBevacizumabBevacizumab approved in US
NSCLC; later ovarian, cervical, RCC, glioblastoma, HCC
- 2006ApprovalHPV quadrivalent vaccine (types 6, 11, 16 and 18)HPV quadrivalent vaccine (types 6, 11, 16 and 18) approved in EU
Prevention of premalignant genital lesions, cervical cancer and genital warts from age 9 (Gardasil); anal lesions and cancer added later
- 2006ApprovalHPV quadrivalent vaccine (types 6, 11, 16 and 18)HPV quadrivalent vaccine (types 6, 11, 16 and 18) approved in US
Prevention of cervical, vulvar and vaginal cancers and precancers and genital warts caused by HPV 6, 11, 16 and 18 in females 9 to 26 (males 2009; anal cancer 2010); superseded by Gardasil 9
- 2006MilestoneNonavalent HPV vaccineFirst HPV vaccine (Gardasil) approved
A milestone in how this cancer is treated.
- 2006MilestoneHPV & HBV vaccinationHPV vaccine approved
A milestone in how this cancer is treated.